RT Journal Article
SR Electronic
T1 Diversity in Parkinson’s disease genetics research: current landscape and future directions
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.07.21266995
DO 10.1101/2021.12.07.21266995
A1 Schumacher-Schuh, Artur F.
A1 Bieger, Andrei
A1 Okunoye, Olaitan
A1 Mok, Kin
A1 Lim, Shen-Yang
A1 Bardien, Soraya
A1 Annuar, Azlina Ahmad
A1 Lopes-Santos, Bruno
A1 Strelow, Matheus Zschornack
A1 Salama, Mohamed
A1 Rao, Shilpa C
A1 Zewde, Yared Zenebe
A1 Dindayal, Saiesha
A1 Azar, Jihan
A1 Prashanth, LK
A1 Rajan, Roopa
A1 Noyce, Alastair J
A1 Okubadejo, Njideka
A1 Rizig, Mie
A1 Lesage, Suzanne
A1 Mata, Ignacio
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/12/08/2021.12.07.21266995.abstract
AB Human genetics research lacks diversity; over 80% of genome-wide association studies (GWAS) have been conducted on individuals of European ancestry. In addition to limiting insights regarding disease mechanisms, disproportionate representation can create disparities preventing equitable implementation of personalized medicine. This systematic review provides an overview of research involving Parkinson’s disease (PD) genetics in under-represented populations (URP), and sets a baseline to measure the future impact of current efforts in those populations.We searched PubMed and EMBASE until October 2021 using search strings for “PD”, “genetics”, the main “URP”, and “lower-to-upper-middle-income countries”. Inclusion criteria were original studies, written in English, reporting genetic results on PD patients from non-European populations. Two levels of independent reviewers identified and extracted relevant information.We observed considerable imbalances in PD genetic studies among URP. Asian participants from China were described in the majority of the articles published (61%), but other populations were less well studied, for example, Blacks were represented in just 4.0% of the publications. Also, although idiopathic PD was more studied than monogenic forms of the disease, most studies analyzed a limited number of genetic variants. We identified just seven studies using a genome-wide approach published up to 2021 including URP.This review provides insight into the significant lack of population diversity in PD research highlighting the urgent need for better representation. The Global Parkinson’s Genetics Program (GP2) and similar initiatives aim to impact research in URP, and the early metrics presented here can be used to measure progress in the field of PD genetics in the future.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Global Parkinson's Genetics Program (GP2) is a resource project from the Aligning Science Across Parkinson's (ASAP) initiative.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors